ResearchMetabolic liver disease: A summary of major guidelines and identifying opportunities to improve future guidelines
ResearchUpdated Global Consensus Recommendations for Risk Stratification, Treatment Initiation, and Response Monitoring in Metabolic Dysfunction-Associated Steatotic Liver Disease
ResearchSeverity of MASH activity by iron-corrected MRI predicts insulin resistance and cardiometabolic risk in type 2 diabetes
ResearchClinical Care Pathway for the Risk Stratification and Management of Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
ResearchHigh Prevalence of Metabolic Dysfunction-Associated Steatohepatitis With Significant Fibrosis in Primary Care and Endocrinology Clinics
ResearchThe economic burden of MASH: comparison of healthcare resource utilization and costs in patients with probable MASH, without MASH, and with diagnosed MASH
ResearchPan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD
ResearchPrevalence of MASLD in People With Diabetes Has Decreased in the US, but Rates of Liver Fibrosis Are Still on the Rise